Pioglitazone and Lumbar Bone Marrow Fat in Chronic Kidney Disease

• ClinicalTrials.gov Identifier: NCT02739750
• Recruitment Status: Completed
• First Posted: April 15, 2016
• Last Update Posted: January 26, 2022
• Sponsor: Indiana University
• Information provided by (Responsible Party): Ranjani Moorthi, Indiana University

Study Description

Brief Summary:

Chronic Kidney Disease (CKD) is associated with bone changes and very high fracture rates. A component of bone is marrow. Bone marrow fat is increased in patients with CKD compared to those in the normal population of the same age. It is not clear if there will be changes in the marrow fact content in those with CKD on Pioglitazone. In people with normal kidney function, thiazolidinedione group of drugs have had variable effects on bone marrow fat content, as measured by MRS. This is important as changes in marrow fat are likely related to changes in the bone in patients with chronic kidney disease.

Condition or disease	Intervention/treatment
Polycystic Kidney Diseases	Other: No intervention

Detailed Description:

If patients consent to participate in the ancillary study of marrow fat changes with pioglitazone, those that are randomized to placebo or 15 mg pioglitazone for 12 months (per the criteria in the main study) will also undergo magnetic resonance spectroscopy (MRS) of the lumbar spine at L1, L2 and L3. MR spectroscopy of the lumbar spine (if they choose as this is ancillary study) will be performed 3 times over the course of the study.

Study Design

• Study Type: Observational
• Actual Enrollment: 35 participants
• Observational Model: Cohort
• Time Perspective: Prospective
• Official Title: Pioglitazone and Lumbar Bone Marrow Fat in Chronic Kidney Disease (CKD) Sub-study to Protocol Number 1308084213
• Actual Study Start Date: January 2016
• Actual Primary Completion Date: October 2019
• Actual Study Completion Date: October 2019

Groups and Cohorts

Intervention Details:

• Other: No intervention
  There is no intervention for this study. It is a MRS.

Outcome Measures

Primary Outcome Measures :

1. The percent change in the bone marrow lipid fraction averaged between L2, L3 and L4 at baseline to 12 months and 12 months to 24 months. [ Time Frame: Baseline, 12 months, 24 months ]
   Subjects will undergo and MRI at Baseline, 12 months, and 24 months to measure bone marrow.

Eligibility Criteria

• Ages Eligible for Study: 18 Years to 55 Years (Adult)
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: No
• Sampling Method: Probability Sample

Study Population

PKD subjects that consent to the FDA study, number 1308084213, will be approached for consenting for this bone marrow fat study.

Subject must be enrolled in NCT#02697617

Criteria

Inclusion Criteria:

• Included subjects will be those who consent to the study of Pioglitazone in ADPKD (Protocol number 1308084213). Therefore inclusion and exclusion criteria are the same as for that study. Subjects will NOT be offered participation in the bone marrow fat study till after they consent for the FDA approved study. Subjects who withdraw from the FDA approved study will be withdrawn from this protocol.

Inclusion/Exclusion Criteria for NCT#02697617

• Male or female ADPKD patients aged 18-55
• eGFR at or above ≥ 50 ml/min/1.73 m2 by 4 parameter MDRD or CKD-Epiformulas
• normal liver enzymes (ALT/AST)
• fasting blood glucose between 70 and120
• for female patients, a willingness to use double contraception to avoid pregnancy while in study
• able to give informed consent
• In the opinion of the investigator, high likelihood of progressive kidney disease

Exclusion Criteria:

• diabetes, defined as any of the following: fasting blood sugar > 130 times two, HgbA1C > 7, on any blood sugar lowering medication, or past diagnosis of diabetes not occurring during pregnancy
• uncontrolled hypertension, defined as systolic > 150, diastolic > 90 despite an attempt by physician to titrate medications
• history of impaired systolic function (ejection fraction < 50%) by previous ECHO or known ischemic cardiovascular disease
• findings suggestive of a kidney disease other than ADPKD
• systemic illness requiring immunosuppressive or anti-inflammatory agents
• congenital absence of a kidney or history of a total nephrectomy
• history of cyst reduction or partial nephrectomy
• history of renal cyst aspiration within the previous year
• History of bladder cancer, or gross hematuria
• inability to undergo MRI due to implantable devices or foreign objects that preclude MRI
• active renal transplant
• allergy or sensitivity to any of the components of the test materials
• institutionalized
• currently pregnant or plans to become pregnant during the study

Contacts and Locations

Locations

United States, Indiana

University Hospital

Indianapolis, Indiana, United States, 46202

Sponsors and Collaborators

Indiana University

Investigators

• Principal Investigator: Ranjani Moorthi, MD; Faculty

More Information

• Responsible Party: Ranjani Moorthi, Assistant Professor, Division of Nephrology, Indiana University
• ClinicalTrials.gov Identifier: NCT02739750
• Other Study ID Numbers: Indiana U 1511993513
• First Posted: April 15, 2016
• Last Update Posted: January 26, 2022
• Last Verified: January 2022

Individual Participant Data (IPD) Sharing Statement:

• Plan to Share IPD: No

Additional relevant MeSH terms:

Kidney Diseases; Renal Insufficiency, Chronic; Polycystic Kidney Diseases; Urologic Diseases; Female Urogenital Diseases; Female Urogenital Diseases and Pregnancy Complications; Urogenital Diseases; Male Urogenital Diseases; Renal Insufficiency; Chronic Disease; Disease Attributes; Pathologic Processes; Kidney Diseases, Cystic; Abnormalities, Multiple; Congenital Abnormalities; Ciliopathies; Genetic Diseases, Inborn